What is Dyne Therapeutics, Inc.'s debt issuance costs?

Dyne Therapeutics, Inc. (DYN) reported debt issuance costs of $30K in Q1 2026.

What does debt issuance costs mean?

Cash paid for fees, legal costs, and underwriting discounts associated with issuing new debt.

Dyne Therapeutics, Inc. DYN Debt Issuance Costs

Debt Issuance Costs at other companies

Arrowhead ResearchARWR

$18.72M—

Edgewise Therapeutics, Inc.EWTX

$38K—

Scholar RockSRRK

$1.31M—

Denali Therapeutics Inc.DNLI

$81K—

BioCryst PharmaceuticalsBCRX

$4.95M—

BioMarin PharmaceuticalsBMRN

——

Other financials

Income statement

See full

Operating income-$125.3M-2.4%

Net income-$120.9M-4.8%

EPS (diluted)-$0.73+30.5%

Balance sheet

See full

Cash & equivalents$753.1M+59.5%

Total debt$168.7M+623%

Total equity$865.1M+29.3%

Total assets$1.1B+49.8%

Cash flow

See full

Operating cash flow-$144.9M-36.9%

CapEx$221.0K-77.5%

Free cash flow-$145.1M-35.8%

Valuation

See full

Market cap$3.35B+153%

Returns & leverage

See full

Return on equity-58.9%-4.4pp

Debt / equity0.2×+0.2×

Current ratio19.9×-0.4×

Where this comes from

Reported directly by Dyne Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfDebtIssuanceCosts.

The official record: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dyne Therapeutics, Inc.'s debt issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Dyne Therapeutics, Inc.'s debt issuance costs?: Dyne Therapeutics, Inc. (DYN) reported debt issuance costs of $30K in Q1 2026.
What does debt issuance costs mean?: Cash paid for fees, legal costs, and underwriting discounts associated with issuing new debt.